KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Preferred Stock Liabilities (2017)

Moderna (MRNA) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $1.2 billion as the latest value for Q4 2017.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $1.2 billion in Q4 2017 year-over-year; TTM through Dec 2017 was $1.2 billion, a N/A change, with the full-year FY2017 number at $1.2 billion, changed N/A from a year prior.
  • Preferred Stock Liabilities was $1.2 billion for Q4 2017 at Moderna.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $1.2 billion in Q4 2017 to a low of $1.2 billion in Q4 2017.